These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32600895)

  • 1. Extent and distribution of peritoneal disease in patients undergoing cytoreductive surgery for first platinum sensitive recurrence in ovarian cancer and its potential therapeutic implications.
    Bhatt A; Bakrin N; Gertych W; Kammar P; Parikh L; Sheth S; Shaikh S; Devouassoux-Shisheboran M; Glehen O
    Eur J Surg Oncol; 2020 Dec; 46(12):2276-2282. PubMed ID: 32600895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence- results of a prospective multi-centre study.
    Bhatt A; Sinukumar S; Parikh L; Mehta S; Shaikh S; Jumle N; Kammar P
    Eur J Surg Oncol; 2021 Aug; 47(8):2150-2157. PubMed ID: 33875284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications.
    Bhatt A; Bakrin N; Kammar P; Mehta S; Sinukumar S; Parikh L; Shaikh S; Mishra S; Mallaya M; Kepenekian V; Benzerdjeb N; Glehen O
    Eur J Surg Oncol; 2021 Jan; 47(1):181-187. PubMed ID: 33071172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO).
    Bhatt A; Sinukumar S; Mehta S; Damodaran D; Zaveri S; Kammar P; Mishra S; Parikh L; Ranade R; Penumadu P; Rajan F
    Eur J Surg Oncol; 2019 Apr; 45(4):666-671. PubMed ID: 30661922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?
    Bhatt A; Yonemura Y; Mehta S; Benzerdjeb N; Kammar P; Parikh L; Shah MY; Shaikh S; Prabhu A; Mishra S; Sinukumar S; Kepenekian V; Bakrin N; Passot G; Glehen O
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):582-589. PubMed ID: 31757660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
    Sinukumar S; Rajan F; Mehta S; Damodaran D; Zaveri S; Kammar P; Bhatt A
    Eur J Surg Oncol; 2021 Jan; 47(1):75-81. PubMed ID: 30857879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study.
    Bhatt A; Yonemura Y; Benzerdjeb N; Mehta S; Mishra S; Parikh L; Kammar P; Shah MY; Prabhu A; Shaikh S; Patel MD; Isaac S; Glehen O
    Eur J Surg Oncol; 2019 Dec; 45(12):2398-2404. PubMed ID: 31337527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
    Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma.
    Lee EYP; An H; Perucho JAU; Chiu KWH; Hui ES; Chu MMY; Ngan HYS
    Eur Radiol; 2020 Oct; 30(10):5551-5559. PubMed ID: 32405751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index.
    Bhatt A; Rousset P; Benzerdjeb N; Kammar P; Mehta S; Parikh L; Goswami G; Shaikh S; Kepenekian V; Passot G; Glehen O
    Colorectal Dis; 2020 Dec; 22(12):2123-2132. PubMed ID: 32940414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study.
    Bhatt A; Kammar P; Sinukumar S; Parikh L; Jumle N; Shaikh S; Mehta S
    Ann Surg Oncol; 2021 Feb; 28(2):1118-1129. PubMed ID: 32748154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
    Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
    J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
    Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction.
    Bhatt A; Glehen O
    Ann Surg Oncol; 2020 May; 27(5):1458-1470. PubMed ID: 31965374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.